• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

    10/13/22 8:00:00 AM ET
    $GENE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GENE alert in real time by email

    ORLANDO, FL / ACCESSWIRE / October 13, 2022 / RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Interview highlights:

    In the exclusive RedChip Money Report interview, Genetic Technologies Limited's CEO Simon Morriss discusses the Company's expanded portfolio of tests, global relationships and partnerships, revenue growth channels, reported five consecutive quarters of growth, and much more.

    Access this interview in its entirety at https://www.genetechinfo.com/interview_access

    About The RedChip Money Report®

    The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

    About Genetic Technologies Limited

    Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company's Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. For more information, please visit www.genetype.com.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Forward Looking Statements

    This press release may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/720280/Genetic-Technologies-Limited-Interview-to-Air-on-Bloomberg-US-on-the-RedChip-Money-ReportR

    Get the next $GENE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GENE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GENE
    Leadership Updates

    Live Leadership Updates

    See more
    • Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

      MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

      9/11/24 8:15:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary

      MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited.  More r

      7/16/24 8:00:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • GTG to launch U.S. Customer Digital Media Sales Campaign

      MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, "Company", "GTG"))), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG's strategy ensures that the company's geneType Risk Assessment test portfolio will be

      2/28/24 8:00:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GENE
    Financials

    Live finance-specific insights

    See more
    • BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog

      10/11/24 9:00:00 AM ET
      $BIVI
      $BOXL
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corp

      4/12/24 9:00:00 AM ET
      $BIVI
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a

      12/29/23 9:00:00 AM ET
      $BIVI
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $GENE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GENE
    SEC Filings

    See more
    • BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog

      10/11/24 9:00:00 AM ET
      $BIVI
      $BOXL
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • Join Genetic Technology's Exclusive Live Investor Webinar and Q&A Session on October 2

      MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies")), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies' senior leadership who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, along with progress on its recent move to a capital light model. Genetic Technologies' EasyDNA platform has over $7m in annual recur

      9/23/24 8:30:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

      MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

      9/11/24 8:15:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      12/12/24 8:00:15 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      12/2/24 8:00:04 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      11/20/24 8:00:07 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genetic Technologies Ltd (Amendment)

      SC 13G/A - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)

      2/14/24 2:14:47 PM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genetic Technologies Ltd

      SC 13G - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)

      2/13/23 10:20:55 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care